New hope for hard-to-treat lymphoma: drug combo aims to control relapsed disease
NCT ID NCT04989621
First seen Apr 24, 2026 · Last updated Apr 25, 2026 · Updated 1 time
Summary
This study tests whether a combination of two drugs (orelabrutinib and rituximab) followed by long-term orelabrutinib can control follicular lymphoma that has returned or stopped responding to prior therapy. About 32 adults with certain types of follicular lymphoma will receive the treatment. The goal is to shrink tumors and delay progression, but patients will need ongoing medication to maintain control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong General Hospital
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,
NOT_YET_RECRUITINGGuangzhou, Guangdong, 51000, China
Contact
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,
RECRUITINGGuangzhou, Guangdong, 51000, China
Contact
Conditions
Explore the condition pages connected to this study.